Cell Therapy Catapult appoints CSO

Professor Johan Hyllner takes up the role

Professor Johan Hyllner

The Cell Therapy Catapult, which is focused on the development of the UK cell therapy industry, has appointed Professor Johan Hyllner to its executive management team as Chief Scientific Officer (CSO). He joins from French company Cellectis, where he was CSO for Cellectis Stem Cells, and has significant experience of directing scientific programmes in industry and academia.

Hyllner takes responsibility for external scientific relations, assessment of candidate projects and technical oversight of preclinical programmes. He has held a number of management roles in the cell therapy industry over 15 years, at companies such as Cellartis, Vitrolife and Scandinavian QC Laboratories.